“Second-Line Treatment With Axitinib: An Effective and Well-Tolerated Weapon in the Therapeutic Sequence of Clear Cell Renal Cell Carcinoma”. Working Paper of Public Health, vol. 4, no. 1, June 2015, https://doi.org/10.4081/wpph.2015.6697.